Ekkehard Schütz, Julia Beck, Donald Peter Braun, Howard B. Urnovitz , et al. “Combining Genome Change Index (GCI) and liquid biopsy to predict and monitor therapeutic responses”, J Clin Oncol 33, 2015 (suppl; abstr e22020).
Genomic instability of tumor cells has been associated with a poor prognosis. However, impaired DNA repair pathways leading to genomic instability are also described to increase tumor sensitivity to DNA damaging agents. A comprehensive Genomic Change Index (GCI) as an indicator of defective DNA repair is proposed as a potential predictor of cytotoxic chemotherapy (chemo) response. Cell-free tumor DNA (cftDNA) has the potential to provide minimally invasive patient specific biomarkers to monitor tumor burden (liquid biopsy).
Read the full text on: http://meetinglibrary.asco.org/content/152454-156